Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-4-30
pubmed:abstractText
Recent studies have shown the expression of a stem cell marker protein, nestin, in nascent blood vessels in nestin-driven green fluorescent protein (ND-GFP) transgenic nude mice. In the present study, we visualized tumor angiogenesis and evaluated the antiangiogenic efficacy of CPT-11 in ND-GFP nude mice using dual-color fluorescence imaging. We orthotopically implanted ND-GFP nude mice with the human cancer cell line HCT-116 expressing red fluorescent protein (RFP). The mice were treated with CPT-11 at 40 mg/kg on days 7, 10, 14. Tumor angiogenesis was imaged and visualized by dual-color fluorescence imaging on day 17, three days after the last CPT-11 treatment. Tumor volume and the mean nascent blood vessel density were determined and compared to the control mice. The growing tumor had high expressions of nestin in the nascent blood vessels. The nascent blood vessels showed co-localization of the endothelial-cell-specific marker CD-31 under immunohistochemical staining. The nascent blood vessels were highly visible and their density was determined. ND-GFP nude mice that were administered CPT-11 showed significant reduction in the mean nascent blood vessel density and tumor volume. The dual-color model of ND-GFP transgenic nude mice orthotopically implanted with HCT-116 expressing RFP proved to be effective in visualizing and quantitating tumor growth and tumor angiogenesis. The results showed that CPT-11 is an effective inhibitor of angiogenesis and provided strong implications for wider clinical application of CPT-11 for colon cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
713-8
pubmed:meshHeading
pubmed-meshheading:17465193-Animals, pubmed-meshheading:17465193-Antineoplastic Agents, Phytogenic, pubmed-meshheading:17465193-Camptothecin, pubmed-meshheading:17465193-Colonic Neoplasms, pubmed-meshheading:17465193-Female, pubmed-meshheading:17465193-Green Fluorescent Proteins, pubmed-meshheading:17465193-HCT116 Cells, pubmed-meshheading:17465193-Humans, pubmed-meshheading:17465193-Intermediate Filament Proteins, pubmed-meshheading:17465193-Luminescent Proteins, pubmed-meshheading:17465193-Male, pubmed-meshheading:17465193-Mice, pubmed-meshheading:17465193-Mice, Inbred C57BL, pubmed-meshheading:17465193-Mice, Nude, pubmed-meshheading:17465193-Mice, Transgenic, pubmed-meshheading:17465193-Microscopy, Fluorescence, pubmed-meshheading:17465193-Neovascularization, Pathologic, pubmed-meshheading:17465193-Nerve Tissue Proteins, pubmed-meshheading:17465193-Recombinant Fusion Proteins, pubmed-meshheading:17465193-Xenograft Model Antitumor Assays
pubmed:articleTitle
The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer.
pubmed:affiliation
AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA.
pubmed:publicationType
Journal Article